Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Ozempic for blood sugar control and Wegovy for weight loss both use different levels of semaglutide, a GLP-1 agonist. Victoza and Saxenda use another GLP-1 agonist, liraglutide.

The global hype around Wegovy, which is made for weight loss, stemmed from Ozempic, which was created as an anti-diabetic ...